OverviewChartProfileKey statisticsFinancialsNews
Derivatives
TraderScreen

ABBVIE/  US00287Y1091  /

Euronext Milan
23/05/2024  12:19:21 Chg. - Volume Bid17:35:07 Ask17:35:07 Market Capitalization Dividend Y. P/E Ratio
147.10EUR - 2
Turnover: 297.24		 -Bid Size: - -Ask Size: - 255.8 bill.EUR - -
GlobeNewswire 11:18 CERE (NASDAQ) ALERT: Cerevel’s $45 Merger Offer From AbbVie is Under Investigation; Contact BFA Law ...
GlobeNewswire 24/05 Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7...
GlobeNewswire 23/05 Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine recept...
GlobeNewswire 22/05 Over 130 Resident Dermatologists Receive In-Depth Cosmetic Training From Renowned ASDS Member Physic...
GlobeNewswire 22/05 Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $57...
GlobeNewswire 22/05 CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference
GlobeNewswire 22/05 Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $57...
GlobeNewswire 22/05 Anavex Life Sciences Announces Expansion of Leadership Team
GlobeNewswire 22/05 OSE Immunotherapeutics and Boehringer Ingelheim expand collaboration to develop first-in-class treat...
GlobeNewswire 21/05 COUR Pharmaceuticals Appoints Paul M. Peloso, MD, as Chief Medical Officer
GlobeNewswire 21/05 BREAKING CEREVEL INVESTIGATION: BFA Law Is Investigating the $45 Per CERE (Nasdaq) Share Offer by Ab...
GlobeNewswire 21/05 Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
GlobeNewswire 17/05 INVESTIGATION ANNOUNCEMENT: BFA Law Announces an Ongoing Investigation into the Merger between Cerev...
GlobeNewswire 16/05 CytomX Therapeutics Announces New Employment Inducement Grants
GlobeNewswire 16/05 Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer
GlobeNewswire 14/05 CEREVEL THERAPEUTICS HOLDINGS, INC. (NASDAQ: CERE) INVESTIGATION ALERT: Is $45 per CERE Share Enough...
GlobeNewswire 14/05 Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024
GlobeNewswire 14/05 Nouscom Appoints Leading Cancer Drug Development Expert, Neil Gallagher, MD, PhD, as Independent Adv...
GlobeNewswire 14/05 In NCLA Amicus Win, and FTC Amicus Loss, Second Circuit Upholds Decision Dismissing Antitrust Suit
GlobeNewswire 13/05 Royalty Pharma to Present at Upcoming Investor Conferences
GlobeNewswire 11/05 SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates LABP, DOMA, FXNC
GlobeNewswire 09/05 Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan
GlobeNewswire 09/05 Royalty Pharma Reports First Quarter 2024 Results
GlobeNewswire 09/05 Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab
GlobeNewswire 09/05 Nxera Pharma’s partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of...